{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:00:43Z","timestamp":1777636843500,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"31","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.vaccine.2022.05.060","type":"journal-article","created":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T07:33:24Z","timestamp":1654328004000},"page":"4150-4159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety and immunogenicity of a quadrivalent seasonal influenza vaccine adjuvanted with hydroxypropyl-\u03b2-cyclodextrin: A phase 1 clinical trial"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8451-9501","authenticated-orcid":false,"given":"Akane","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumiyuki","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Temiz\u00f6z","family":"Burcu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Shibahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takato","family":"Kusakabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etsushi","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6728-3872","authenticated-orcid":false,"given":"Ken J.","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kumanogoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.05.060_b0005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.7883\/yoken.JJID.2014.092","article-title":"Evaluation of estimated number of influenza patients from national sentinel surveillance using the national database of electronic medical claims","volume":"68","author":"Nakamura","year":"2015","journal-title":"Jpn J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.05.060_b0010","doi-asserted-by":"crossref","unstructured":"Murakami Y, Hashimoto S, Kawado M, Ohta A, Taniguchi K, Sunagawa T, et al. Estimated number of patients with influenza A(H1)pdm09, or other viral types, from 2010 to 2014 in Japan. PLoS One 2016;11: e0146520. https:\/\/doi.org\/10.1371\/journal.pone.0146520.","DOI":"10.1371\/journal.pone.0146520"},{"key":"10.1016\/j.vaccine.2022.05.060_b0015","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/aje\/kwt235","article-title":"Age- and sex-related risk factors for influenza-associated mortality in the United States between 1997\u20132007","volume":"179","author":"Quandelacy","year":"2014","journal-title":"Am J Epidemiol"},{"issue":"5","key":"10.1016\/j.vaccine.2022.05.060_b0020","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1086\/341407","article-title":"Encephalitis and Encephalopathy Associated with an Influenza Epidemic in Japan","volume":"35","author":"Morishima","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2022.05.060_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00044011-199815010-00001","article-title":"Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines","volume":"15","author":"Beyer","year":"1998","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.vaccine.2022.05.060_b0030","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJM197703102961012","article-title":"Influenza vaccine: Split- product versus whole-virus types\u2014How do they differ?","volume":"296","author":"Gross","year":"1977","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.05.060_b0035","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.4049\/jimmunol.1402027","article-title":"Hydroxypropyl-\u03b2- cyclodextrin spikes local inflammation that induces Th2 cell and T follicular helper cell responses to the coadministered antige","volume":"194","author":"Onishi","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2022.05.060_b0040","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/S0264-410X(03)00071-9","article-title":"The annual production cycle for influenza vaccine","volume":"21","author":"Gerdil","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.05.060_b0045","unstructured":"WHO Global Influenza Surveillance Network Manual for the laboratory diagnosis and virological surveillance of influenza 2011."},{"key":"10.1016\/j.vaccine.2022.05.060_b0050","unstructured":"Clinical evaluation of new vaccines | European Medicines Agency n.d. https:\/\/www.ema.europa.eu\/en\/clinical-evaluation-new-vaccines (accessed January 12, 2021)."},{"key":"10.1016\/j.vaccine.2022.05.060_b0055","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3390\/vaccines2040707","article-title":"Overview of serological techniques for influenza vaccine evaluation: Past, present and future","volume":"2","author":"Trombetta","year":"2014","journal-title":"Vaccines"},{"issue":"9708","key":"10.1016\/j.vaccine.2022.05.060_b0060","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(09)62003-1","article-title":"Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"375","author":"Liang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.05.060_b0065","doi-asserted-by":"crossref","first-page":"6959","DOI":"10.1016\/j.vaccine.2009.08.101","article-title":"MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety database","volume":"49","author":"Pellegrini","year":"2009","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2022.05.060_b0070","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0264-410X(98)00185-6","article-title":"Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons","volume":"17","author":"Minutello","year":"1999","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2022.05.060_b0075","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S1473-3099(13)70046-X","article-title":"AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: A phase 3 randomised trial","volume":"13","author":"McElhaney","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.05.060_b0080","doi-asserted-by":"crossref","unstructured":"Ferguson M, Risi G, Davis M, Sheldon E, Baron M, Li P, et al. Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant. J Infect Dis 2012;205:733\u201344. https:\/\/doi.org\/10.1093\/infdis\/jir641.","DOI":"10.1093\/infdis\/jir641"},{"key":"10.1016\/j.vaccine.2022.05.060_b0085","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fimmu.2013.00114","article-title":"Mechanisms of action of adjuvants","volume":"4","author":"Awate","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2022.05.060_b0090","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.immuni.2011.03.019","article-title":"Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanism","volume":"34","author":"Kuroda","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2022.05.060_b0095","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1021\/js960213f","article-title":"Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation","volume":"86","author":"Irie","year":"1997","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2022.05.060_b0100","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.fct.2005.03.007","article-title":"2-Hydroxypropyl-\u03b2-cyclodextrin (HP-\u03b2-CD): A toxicology review","volume":"43","author":"Gould","year":"2005","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.vaccine.2022.05.060_b0105","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.addr.2007.05.012","article-title":"Cyclodextrins as pharmaceutical solubilizers","volume":"59","author":"Brewster","year":"2007","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"10.1016\/j.vaccine.2022.05.060_b0110","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1080\/21645515.2017.1415684","article-title":"Adjuvanted influenza vaccines","volume":"14","author":"Tregoning","year":"2018","journal-title":"Adjuvanted influenza vaccines Hum Vaccin Immunother"},{"issue":"6","key":"10.1016\/j.vaccine.2022.05.060_b0115","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1128\/CVI.05726-11","article-title":"Evaluation of influenza virus A\/H3N2 and B vaccines on the basis of cross-reactivity of postvaccination human serum antibodies against influenza viruses A\/H3N2 and B isolated in MDCK cells and embryonated hen eggs","volume":"19","author":"Kishida","year":"2012","journal-title":"Clin Vaccine Immunol"},{"issue":"47","key":"10.1016\/j.vaccine.2022.05.060_b0120","doi-asserted-by":"crossref","first-page":"7536","DOI":"10.1016\/j.vaccine.2010.08.064","article-title":"An influenza B outbreak during the 2007\/2008 winter among appropriately immunized elderly people living in a nursing home","volume":"28","author":"Camilloni","year":"2010","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2022.05.060_b0125","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/infdis\/jis427","article-title":"Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons","volume":"206","author":"Jackson","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.05.060_b0130","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.4161\/hv.29393","article-title":"A dose-ranging study of MF59\u00ae-adjuvanted and non-adjuvanted A\/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination","volume":"10","author":"Reisinger","year":"2014","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2022.05.060_b0135","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1016\/j.vaccine.2012.03.017","article-title":"A randomized clinical trial to identify the optimal antigen and MF59 \u00ae adjuvant dose of a monovalent A\/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects","volume":"30","author":"Hatz","year":"2012","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2022.05.060_b0140","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1073\/pnas.0813390106","article-title":"Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels","volume":"106","author":"Galli","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2022.05.060_b0145","doi-asserted-by":"crossref","first-page":"330","DOI":"10.4049\/jimmunol.166.1.330","article-title":"Complementary effects of TNF and lymphotoxin on the formation of germinal center and follicular dendritic cells","volume":"166","author":"Wang","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2022.05.060_b0150","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1126\/science.271.5253.1289","article-title":"Role of lymphotoxin and the type I TNF receptor in the formation of germinal centers","volume":"271","author":"Matsumoto","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2022.05.060_b0155","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1084\/jem.184.4.1397","article-title":"Immune and inflammatory responses in TNF\u223c-deficient mice: A critical requirement for TNFoL in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response","volume":"184","author":"Pasparakis","year":"1996","journal-title":"J Exp Med"},{"issue":"18","key":"10.1016\/j.vaccine.2022.05.060_b0160","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood-2009-10-249177","article-title":"Cellular source and molecular form of TNF specify its distinct functions in organization of secondary lymphoid organs","volume":"116","author":"Tumanov","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2022.05.060_b0165","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nri1334","article-title":"T-cell-B-cell cooperation","volume":"4","author":"Mitchison","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2022.05.060_b0170","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/ni832","article-title":"Distinct lineages of THI cells have differential capacities for memory cell generation in vivo","volume":"3","author":"Wu","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2022.05.060_b0175","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nri2274","article-title":"T-cell quality in memory and protection: Implications for vaccine design","volume":"8","author":"Seder","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2022.05.060_b0180","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.vaccine.2005.08.105","article-title":"Antibody response to influenza vaccination in the elderly: A quantitative review","volume":"24","author":"Goodwin","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.05.060_b0185","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(05)17984-7","article-title":"Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review","volume":"365","author":"Jefferson","year":"2005","journal-title":"Lancet"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22006776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22006776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:14:26Z","timestamp":1759403666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22006776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":37,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0264410X22006776"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.05.060","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of a quadrivalent seasonal influenza vaccine adjuvanted with hydroxypropyl-\u03b2-cyclodextrin: A phase 1 clinical trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.05.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}